Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Mar 28, 2005; 11(12): 1854-1858
Published online Mar 28, 2005. doi: 10.3748/wjg.v11.i12.1854
Published online Mar 28, 2005. doi: 10.3748/wjg.v11.i12.1854
Table 1 Microscopic examination of liver biopsy in patients with chronic hepatitis C according to Scheuer classification scale[13].
Histological liver examination Grading (stage) | Responders | Non-responders |
Portal activity of inflammation: 1/2/3/4 (n) | 3/7/16/0 | 1/5/12/0 |
Lobular activity of inflammation: 1/2/3/4 (n) | 12/9/1/0 | 6/11/1/0 |
Staging (stage): 1/2/3/4 (n) | 19/3/0/0 | 9/7/2/0 |
Table 2 Biochemical and hematological parameters during IFNα2b with RBV therapy in chronic hepatitis C.
Time of the treatment | Alanine aminotran-sferase (U/L) | Prothrombin index (%) | Platelets (1×103/mL) | Erythrocytes(1×106/mL) | Leukocytes(1×103/mL) |
0 | 106±50 | 95±9.6 | 208±34 | 4.6±0.5 | 6.3±2.1 |
16 wk | 24.4±16.7 | 97±6.4 | 198±46 | 4.0±0.5 | 5.1±2.3 |
32 wk | 19.6±13.2 | 99±9.2 | 202±63 | 3.9±0.6 | 4.6±1.5 |
48 wk | 35±67 | 100±7.4 | 193±62 | 4.1±0.6 | 4.9±1.9 |
Table 3 Level of GF in chronic hepatitis C during IFNα2b with RBV therapy (mean±SD).
HGF (pg/mL) | EGF (pg/mL) | TPO (pg/mL) | PDGF (pg/mL) | |
Healthy | 748±91 | 12.9±3.3 | 47.6±16.5 | 473.2±145 |
0 (I) | 983±227 | 18.4±7.1a | 55.5±17.2 | 387±116 |
16 wk (II) | 752±277 | 12.7±6.3 | 71±56.3 | 334±84.8a |
32 wk (III) | 783±297 | 13.9±5.2 | 67.5±18.3a | 342±84.5a |
48 wk (IV) | 770±278 | 15.8±5.7 | 62.5±28.1 | 330±138a |
P value | NS | I:II P<0.01 | NS | I:II P<0.02 |
I:III P<0.01 | I:III P<0.03 | |||
II:IV P<0.04 |
Table 4 Serum concentrations of GF in virological responders and non-responders, Student’s t test (mean±SD).
Growth factor | Responders | Non-responders | P | |||
0 wk | 48 wk | 0 wk | 48 wk | 0 wk | 48 wk | |
HGF (pg/mL) | 873±210 | 792±198 | 919±257 | 742±260 | 0.6 | 0.7 |
EGF (pg/mL) | 16.8±5.8 | 16.1±6.2 | 20.4±8.4 | 15.5±4.9 | 0.2 | 0.8 |
TPO (pg/mL) | 48.4±14 | 68.8±13 | 64.2±17.1 | 54.8±12 | 0.03 | 0.2 |
PDGF (pg/mL) | 425±111 | 292±180 | 340±111 | 377±98 | 0.1 | 0.1 |
Table 5 Correlation of GF in the course of IFNα2b with RBV therapy with grade activity of inflammation and fibrosis in the liver in responders (R) and non-responders (NR). Histological classification according to Scheuer[13].
Growth factor | Inflammation activity, grading | Fibrosis hepatitis,staging | ||
Periportal | Intralobular | |||
HGF | R | NR | r = 0.4, P<0.05 | r = 0.5, P<0.05 |
NS | NS | r = 0.5, P<0.03 | r = 0.4, P<0.03 | |
EGF | R | r=–0.6, P<0.003 | r = –0.5, P<0.01 | NS |
NR | NS | NS | NS | |
TPO | R | r=0.5, P<0.01 | r = 0.6, P<0.004 | r = 0.5, P<0.01 |
NR | NS | NS | r = 0.4, P<0.04 | |
PDGF | R | r=–0.5, P<0.01 | r = –0.5, P<0.02 | NS |
NR | NS | NS | NS |
- Citation: Anatol P, Robert F, Danuta P. Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C. World J Gastroenterol 2005; 11(12): 1854-1858
- URL: https://www.wjgnet.com/1007-9327/full/v11/i12/1854.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i12.1854